Takeshi Hatanaka
Overview
Explore the profile of Takeshi Hatanaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aoki T, Kudo M, Nishida N, Ueshima K, Tsuchiya K, Tada T, et al.
J Gastroenterol
. 2025 Mar;
PMID: 40055288
Background: Achieving complete response (CR) is a desirable goal in early-to-intermediate-stage hepatocellular carcinoma (HCC). While systemic and locoregional therapies show promise, optimal drug discontinuation criteria remain unclear. This study aims...
2.
Shimose S, Saeki I, Ito T, Takeuchi Y, Tani J, Tomonari T, et al.
Hepatol Int
. 2025 Feb;
PMID: 40019708
Background: This study aimed to investigate the changes in oncological resection status in patients with unresectable hepatocellular carcinoma (u-HCC) receiving atezolizumab plus bevacizumab (Atez/Bev) and the impact of conversion therapy...
3.
Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, et al.
Oncology
. 2025 Feb;
:1-23.
PMID: 39900019
Background/aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use of tumor markers as...
4.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39844393
Background And Aim: To assess the relationship between survival outcomes and subtypes of radiological progressive disease (PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atezo/Bev). Methods:...
5.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, et al.
Cancer Med
. 2025 Jan;
14(2):e70618.
PMID: 39840727
Aim: This study aims to investigate the clinical utility of the derived neutrophil-to-lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable...
6.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39762722
Aim: This study aimed to compare the prognostic performance of the risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment. Methods: Among 449...
7.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al.
Sci Rep
. 2025 Jan;
15(1):72.
PMID: 39747852
In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the...
8.
Suga T, Kakizaki S, Naganuma A, Hatanaka T, Takakusagi S, Takizawa D, et al.
JGH Open
. 2025 Jan;
9(1):e70081.
PMID: 39742152
Background: Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment...
9.
Hatanaka T, Hiraoka A, Tada T, Kakizaki S
Liver Cancer
. 2024 Dec;
13(6):669-670.
PMID: 39687039
No abstract available.
10.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, et al.
Hepatol Res
. 2024 Nov;
PMID: 39526824
Aim: Since the development of tremelimumab plus durvalumab (Dur/Tre) for unresectable hepatocellular carcinoma (uHCC), it has been used as not only an initial but also later line treatment in clinical...